New shot therapy targets hard-to-treat skin cancer in phase 2 trial
NCT ID NCT07228442
First seen Nov 15, 2025 · Last updated May 07, 2026 · Updated 21 times
Summary
This study tests a new treatment for people with advanced skin cancer (squamous cell carcinoma) that has stopped responding to or cannot tolerate standard immunotherapy. The treatment is a combination of two drugs (L19IL2 and L19TNF) injected directly into the tumors once a week for up to 4 weeks, with a possible second course. The goal is to see if this approach can shrink tumors and control the disease. About 92 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact
-
Winship Cancer Institute, Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.